EMA Recommends Granting a Marketing Authorisation for Poherdy By Ogkologos - April 10, 2026 240 0 Facebook Twitter Google+ Pinterest WhatsApp It is a biosimilar of pertuzumab which was authorised in the EU in 2013 Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR OncoNPC Classifier Identifies CUP Subgroups Sharing Characteristics with Predicted Primaries and... September 6, 2023 Pirtobrutinib Shows Efficacy in Patients with Heavily Pretreated CLL or SLL... July 18, 2023 Biomarker Analyses in Patients with HER2-positive or HER2-low Gastric and Gastro-oesophageal... May 21, 2024 FOCUS4: Learning from a landmark clinical trial April 25, 2023 Load more HOT NEWS Cancer, COVID-19, and Competing Threats to Indigenous Health College Student Rescues Cats Between Classes, Working 2 Jobs, And Planning... Catch up on Behind the Science 2021 – From funding stream... EMA Recommends Extension of Therapeutic Indications for Cetuximab
